Telomir Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, December 31, 2025 | 34,380,971 | $— | $46,923,433 | $(41,010,063) | $5,913,370 |
| Stock-based compensation | — | — | 39,803 | — | 39,803 |
| Net loss | — | — | — | (990,947) | (990,947) |
| Balances, March 31, 2026 | 34,380,971 | $— | $46,963,236 | $(42,001,010) | $4,962,226 |
| Balances, December 31, 2024 | 29,762,671 | $— | $31,239,895 | $(30,596,858) | $643,037 |
| Stock-based compensation | — | — | 1,375,686 | — | 1,375,686 |
| Net loss | — | — | — | (2,179,828) | (2,179,828) |
| Balances, March 31, 2025 | 34,380,971 | $— | $32,615,581 | $(32,776,686) | $(161,105) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.